ANTX
AN2 THERAPEUTIC (ANTX)
NASDAQ
$4.17+$0.10 (+2.48%)
Price as of Jun 03, 2026 5:53 PM EDT
  • $155.9M
    Market Cap
  • 270.00%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-24.8M
-38.82%
-40.5M
-26.21%
-54.9M
+92.46%
-28.5M
N/A
Depreciation and Amortization Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Operating Expenses
38.1M
-32.89%
56.8M
-18.45%
69.6M
+64.77%
42.3M
N/A
Operating Profit
-38.1M
-32.89%
-56.8M
-18.45%
-69.6M
+64.77%
-42.3M
N/A
Interest Income
2.9M
-46.33%
5.5M
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
2.9M
-46.33%
5.5M
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
1,000
-97.67%
43,000
-99.12%
4.9M
+10,995.56%
-45,000
N/A
Income before Taxes
-35.2M
-31.46%
-51.3M
-20.72%
-64.7M
+51.33%
-42.8M
N/A
Income Taxes
0
N/A
0
N/A
0
N/A
0
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-35.2M
-31.46%
-51.3M
-20.72%
-64.7M
+58.05%
-41.0M
N/A
Net Income from Continuing Operations Applicable to Common
-35.2M
-31.46%
-51.3M
-20.72%
-64.7M
+51.33%
-42.8M
N/A
Basic EPS and Net Income
-1.16
-32.56%
-1.72
-37.23%
-2.74
-1.79%
-2.79
N/A
Diluted EPS and Net Income
-1.16
-32.56%
-1.72
-37.23%
-2.74
-1.79%
-2.79
N/A
Basic Weighted Average Shares
30.2M
+1.30%
29.8M
+26.39%
23.6M
+53.85%
15.3M
N/A
Diluted Weighted Average Shares
30.2M
+1.30%
29.8M
+26.39%
23.6M
+53.85%
15.3M
N/A
Balance Sheet
Cash and Cash Equivalents
19.9M
-6.60%
21.4M
+36.45%
15.6M
-42.51%
27.2M
N/A
Short-Term Investments
38.1M
-38.88%
62.3M
-32.06%
91.6M
+33.13%
68.8M
N/A
Cash and Cash Equivalents and Short-Term Investments
58.0M
-30.64%
83.6M
-22.07%
107.3M
+11.70%
96.1M
N/A
Total Current Assets
59.9M
-30.52%
86.3M
-21.94%
110.5M
+12.05%
98.6M
N/A
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Assets
0
-100.00%
804,000
-22.91%
1.0M
+44.86%
720,000
N/A
Total Assets
62.0M
-32.73%
92.1M
-33.63%
138.7M
+35.28%
102.6M
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
8.7M
+1,002.40%
791,000
-94.37%
14.0M
+95.42%
7.2M
N/A
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
170,000
N/A
N/A
N/A
50,000
-5.66%
53,000
N/A
Total Liabilities
8.9M
-13.17%
10.2M
-27.10%
14.0M
+95.37%
7.2M
N/A
Retained Earnings
-240.9M
+17.09%
-205.8M
+33.23%
-154.5M
+72.15%
-89.7M
N/A
Total Stockholders Equity
53.1M
-35.17%
81.8M
-34.36%
124.7M
+30.75%
95.4M
N/A
Total Shares Outstanding
27.4M
-8.38%
29.9M
+0.60%
29.7M
+53.29%
19.4M
N/A
Cash Flow
Cash from Operating Activities
-29.8M
-39.43%
-49.3M
-7.56%
-53.3M
+59.25%
-33.5M
N/A
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
28.3M
-48.14%
54.6M
+226.14%
-43.3M
+98.79%
-21.8M
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
113,000
-69.62%
372,000
-99.56%
85.0M
+20.81%
70.4M
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-45.67%
+2.71%
-44.47%
-17.12%
-53.65%
N/A
N/A
N/A
Return on Equity
-52.14%
+4.93%
-49.69%
-15.53%
-58.83%
N/A
N/A
N/A
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
6.87
-93.70%
109.05
+1,285.84%
7.87
N/A
N/A
N/A
Cash Ratio
2.29
-91.53%
26.99
+2,322.58%
1.11
N/A
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow